Form 4 for BIO BIO-RAD LABORATORIES, INC.
Accepted 2025-04-24 00:00:00 ET · period of report 2025-04-22 · accession 0001062993-25-007905 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-04-24 | 2025-04-22 | BIO | EDWARDS JEFFREY L | Dir | M - OptEx | $0.00 | +308 | 308 | New | $0 |
| D | 2025-04-24 | 2025-04-22 | BIO | EDWARDS JEFFREY L | Dir | A - Grant | $0.00 | +407 | 407 | New | $0 |
| D | 2025-04-24 | 2025-04-22 | BIO | EDWARDS JEFFREY L | Dir | M - OptEx | $0.00 | -308 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Bio-Rad A Common Stock | 2025-04-22 | M | A | 308 | $0.00 | 308 | D | — | — | (F1) Shares of Class A common stock acquired on the vesting of restricted stock units. |
| 2 | Derivative | Restricted Stock Units | 2025-04-22 | A | A | 407 | $0.00 | 407 | D | $0.00 · — to — | 407 Bio-Rad A Common Stock | (F2) Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. (F3) The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. |
| 3 | Derivative | Restricted Stock Units | 2025-04-22 | M | D | 308 | $0.00 | 0 | D | $0.00 · — to — | 308 Bio-Rad A Common Stock | (F2) Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. (F4) On September 6, 2024, the reporting person was granted 308 restricted stock units, vesting at 100% on the earlier of the first anniversary of the grant date or the date of the Company's next annual stockholder meeting following the grant date. |